Neurocrine Biosciences (NBIX) Change in Inventory (2017 - 2026)

Neurocrine Biosciences' Change in Inventory history runs 10 years deep, the most recent figure standing at -$4.3 million for Q1 2026.

• Quarterly Change in Inventory fell 352.94% year-over-year to -$4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (down 57.53% YoY) and the FY2025 annual result came in at $15.3 million, down 19.9% from the prior year.
• Change in Inventory was -$4.3 million for Q1 2026 at Neurocrine Biosciences, down from $3.4 million in the prior quarter.
• Across five years, Change in Inventory topped out at $12.3 million in Q3 2025 and bottomed at -$4.3 million in Q1 2026.
• A 5-year average of $1.6 million and a median of $300000.0 in 2022 frame the typical range for Change in Inventory.
• Annual changes were most pronounced in 2023 — Change in Inventory tumbled 633.33% — and 2024, when it jumped 1188.89%.
• Neurocrine Biosciences' Change in Inventory stood at -$3.9 million in 2022, then surged by 123.08% to $900000.0 in 2023, then soared by 1188.89% to $11.6 million in 2024, then plunged by 70.69% to $3.4 million in 2025, then slumped by 226.47% to -$4.3 million in 2026.
• Business Quant data shows NBIX's Change in Inventory at -$4.3 million in Q1 2026, $3.4 million in Q4 2025, and $12.3 million in Q3 2025.